Compass Therapeutics (CMPX) CEO has 36,687 shares withheld

Rhea-AI Filing Summary

Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported a Form 4 transaction involving company common stock. On 02/08/2026, 36,687 shares of common stock were withheld by the issuer at $6.52 per share to cover tax withholding obligations tied to vesting restricted stock units.

After this tax withholding, Schuetz beneficially owns 6,603,336 shares of common stock. This includes unvested RSUs: 125,000 shares from a February 8, 2023 grant vesting in four equal annual installments starting February 8, 2024; 318,750 shares from a January 9, 2024 grant vesting annually starting January 9, 2025; and 250,000 shares from a January 2, 2026 grant vesting annually starting January 2, 2027.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schuetz Thomas J.

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	36,687	$6.52	$239K

Holdings After Transaction: Common Stock — 6,603,336 shares (Direct)

Footnotes (1)

1. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). 125,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schuetz Thomas J.

(Last) (First) (Middle)

C/O COMPASS THERAPEUTICS, INC.

80 GUEST ST., SUITE 601

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Compass Therapeutics, Inc. [ CMPX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/08/2026		F(1)		36,687	D	$6.52	6,603,336(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

2. 125,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

	/s/ Thomas J. Schuetz	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Compass Therapeutics (CMPX) report for its CEO?

Compass Therapeutics CEO Thomas J. Schuetz reported issuer share withholding to satisfy tax obligations. On February 8, 2026, 36,687 shares of common stock were withheld in connection with vesting restricted stock units, as disclosed in the Form 4 filing and related explanatory footnote.

How many Compass Therapeutics (CMPX) shares were withheld and at what price?

The Form 4 shows 36,687 shares of Compass Therapeutics common stock withheld by the issuer at $6.52 per share. The filing explains these shares covered tax withholding obligations arising from the vesting of restricted stock units previously granted to Thomas J. Schuetz.

How many Compass Therapeutics (CMPX) shares does Thomas J. Schuetz own after this transaction?

Following the reported tax withholding transaction, Thomas J. Schuetz beneficially owns 6,603,336 shares of Compass Therapeutics common stock. This total includes both currently held shares and multiple grants of unvested restricted stock units that each convert into one common share upon vesting.

What RSU awards does the Compass Therapeutics (CMPX) CEO have outstanding?

The CEO holds unvested RSUs covering 125,000 shares from a February 8, 2023 grant, 318,750 shares from a January 9, 2024 grant, and 250,000 shares from a January 2, 2026 grant. Each RSU represents a contingent right to receive one share of common stock.

What are the vesting schedules for the CEO’s Compass Therapeutics (CMPX) RSUs?

Each RSU grant vests in four equal annual installments, subject to service-based conditions. The 2023 grant began vesting February 8, 2024; the 2024 grant began January 9, 2025; and the 2026 grant will begin vesting on January 2, 2027, according to the disclosure.

Was the Compass Therapeutics (CMPX) CEO’s Form 4 transaction an open-market sale?

The Form 4 describes the 36,687-share transaction as shares withheld by the issuer to cover tax withholding obligations upon RSU vesting. The disclosure characterizes this as tax withholding rather than an open-market sale by Thomas J. Schuetz.